KKR takes Integer Holdings private at $5.7 billion. Medical device carveout season opens.

KKR closed its acquisition of Integer Holdings for $5.7 billion, removing a mid-tier medical-device supplier from public markets and signaling the start of a consolidation wave in cardiac rhythm management and neuromodulation components. Integer manufactures batteries, leads, and enclosures for implantable devices—parts that appear in pacemakers, defibrillators, and neurostimulators sold under other brands. The deal values Integer at roughly 14x trailing EBITDA, a multiple that reflects scarcity value in a supply chain where vertical integration now matters more than scale.

Integer reported $1.49 billion in revenue for 2023, with 63% derived from cardiac and neuromodulation OEMs including Medtronic, Abbott, and Boston Scientific. The company operates 19 manufacturing sites across eight countries, a geographic spread that became a liability during the post-2021 supply-chain crisis but now represents optionality in an era of reshoring mandates. KKR's thesis rests on two levers: margin expansion through site rationalization, and revenue growth by serving the wave of GLP-1-adjacent device demand—obesity patients with improved cardiac outcomes need replacement devices, and Integer makes the components. The private structure lets KKR consolidate sites without quarterly earnings calls.

The deal matters because it removes a rare independent component supplier from a market increasingly controlled by vertically integrated giants. Medtronic and Abbott both produce their own components; Boston Scientific relies on a shrinking pool of third-party manufacturers. Integer's exit leaves two publicly traded peers—Greatbatch's spinoff legacy assets and a handful of private European suppliers—creating a bottleneck for smaller device makers who lack captive manufacturing. KKR now controls leverage in negotiations with both OEMs (who need redundancy) and startups (who need any manufacturing partner at all). The $5.7 billion price also resets the floor for similar carveouts; expect bids for other sub-scale public device companies in the $2-8 billion enterprise-value range within six months.

Operators should track three follow-on events. First, watch for Integer's site consolidation announcements within 90 days—KKR will likely shutter two or three facilities and redirect production to lower-cost geographies, creating short-term supply friction for OEM customers. Second, monitor whether Medtronic or Abbott attempt to acquire smaller component suppliers in response; both have balance-sheet capacity and strategic reasons to prevent KKR from becoming a monopoly supplier. Third, expect KKR to layer in bolt-on acquisitions—likely one European lead-wire manufacturer and one Asian battery supplier—within 18 months, building a vertically integrated platform that resembles the old Greatbatch model before its 2021 breakup.

Integer's delisting removes $1.2 billion in daily trading liquidity from the medical-device index and eliminates a hedge for investors long the major OEMs. The component tier is now a private-equity hunting ground.